TenSixteen Bio is the first company leveraging somatic mosaicism and clonal hematopoiesis (CHIP) to discover and develop novel therapeutics to treat age-related diseases. A Foresite Labs incubated company, TenSixteen Bio evaluates how DNA in our cells changes over the course of our lifetimes, building data sets to measure, understand, and use this evolution to inform drug discovery. The company aims to use its genomic and clinical platform to treat various age-related diseases including cancer and cardiovascular disease.
Location: United States, Massachusetts, Boston
Total raised: $40M
Investors 2
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| 03.02.2022 | GV | gv.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.01.2022 | - | $40M | - |
Mentions in press and media 1
| Date | Title | Description | Source |
| 28.01.2022 | TenSixteen Bio Launches with $40M Funding | SAN FRANCISCO, CA, TenSixteen Bio launches with $40M from Foresite Capital and GV. >> Click... | vcnewsdail... |